Ligand id: 7998

Name: guselkumab

Immunopharmacology Comments
Anti-IL-23 mAbs act upstream of the IL-17/TH17 pathway [3] in autoimmune inflammation. Utilising IL-23-selective biologic therapeutics (that do not act on the TH1 cell immune response) are expected to offer an improved safety profile compared to IL-17-targeting therapeutics. Other anti-IL-23 clinical candidates include tildrakizumab (Sun Pharmaceutical Industries) and risankizumab (AbbVie).
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
First anti-IL-23 biologic therapy to be approved. Approved for the treatment of moderate to severe plaque psoriasis, in patients considered as candidates for systemic therapy or phototherapy.